Patent US5237070A successfully refreshed from Google Patents.
US5237070A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Substituted DI-t-butylphenols
Assignee: Riker Laboratories Inc
•
Filing: 1991-05-16
•
Granted: 1993-08-17
•
Expires: 2011-05-16
Abstract
Abstract Novel compounds which are 2,6-di-t-butylphenols substituted on the 4 position by an anilino group, which anilino group is substituted by a carboxyl substituent, a tetrazolyl substituent or an N-methyltetrazolyl substituent, are useful antiallergic agents. Pharmaceutical compositions containing and pharmacological methods of using such compounds are also disclosed, as are synthetic intermediates for preparing such compounds. Certain of the synthetic intermediates also exhibit useful antiallergic activity.
Inventors
- 👤 Robert A. Scherrer
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 14:19
CPC Classifications
C; C07; C07D; C07D257/00; C07D257/02; C07D257/04; C07C; C07C255/00
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
104 words
A compound of the formula ##STR35## wherein R is hydrogen, lower alkyl, lower alkoxy, lower alkylthio, halogen, amino, lower alkylamino, di(lower alkylamino), lower acylamido, or hydroxy, and n is 0, 1 or 2, with the proviso that if n is 2, all R substituents combined contain no more than 6 carbon atoms; R' is hydrogen, lower alkyl, acetyl or trifluoroacetyl; A is tetrazol-5-yl or N-methyltetrazol-5-yl, B is a carbon-carbon bond, --CH 2 -- or ##STR36## or a derivative of a compound wherein A is tetrazol-5-yl, said derivatives selected from a pharmaceutically acceptable alkali metal salt and an alkaline earth salt of the tetrazolyl moiety.
Claim 2
Dependent Claim
104 words
A compound of the formula ##STR35## wherein R is hydrogen, lower alkyl, lower alkoxy, lower alkylthio, halogen, amino, lower alkylamino, di(lower alkylamino), lower acylamido, or hydroxy, and n is 0, 1 or 2, with the proviso that if n is 2, all R substituents combined contain no more than 6 carbon atoms; R' is hydrogen, lower alkyl, acetyl or trifluoroacetyl; A is tetrazol-5-yl or N-methyltetrazol-5-yl, B is a carbon-carbon bond, --CH 2 -- or ##STR36## or a derivative of a compound wherein A is tetrazol-5-yl, said derivatives selected from a pharmaceutically acceptable alkali metal salt and an alkaline earth salt of the tetrazolyl moiety.
Claim 3
Dependent Claim
10 words
A compound according to claim 1 wherein R is hydrogen.
Claim 4
Dependent Claim
17 words
A compound according to claim 1, wherein --B--A is oriented meta or para to the ##STR37## linking.
Claim 5
Dependent Claim
12 words
A compound according to claim 1, wherein B is a carbon-carbon bond.
Claim 6
Dependent Claim
29 words
A pharmaceutical anti-allergic composition comprising a compound according to claim 1 and a pharmaceutically acceptable vehicle, said compound being present in an amount effective for providing an anti-allergic response.
Claim 7
Dependent Claim
33 words
A method for inhibiting bronchoconstriction due to an allergic response in a mammal wherein a compound according to claim 1 is administered to a mammal in an amount sufficient to cause such inhibition.
Claim 8
Dependent Claim
13 words
A method according to claim 6, wherein said compound is administered by inhalation.
Claim 9
Dependent Claim
12 words
A method according to claim 6, wherein said compound is administered orally.
Claim 10
Dependent Claim
28 words
A method for inhibiting leukotriene synthesis in a mammal comprising administering to said mammal a compound according to claim 1 in an amount effective to inhibit said synthesis.
Claim 11
Dependent Claim
28 words
A method for inhibiting lipoxygenase activity in a mammal comprising administering to said mammal a compound according to claim 1 in an amount effective to inhibit said activity.
Claim 12
Independent Claim
125 words
A method of inhibiting bronchoconstriction due to an allergic response in a mammal wherein an antiallergic compound is administered in an amount sufficient to cause such inhibition, said antiallergic compound being of the formula ##STR38## wherein R is hydrogen, lower alkyl, lower alkoxy, lower alkylthio, halogen, amino, lower alkylamino, di(lower alkylamino), lower acylamido, or hydroxy, and n is 0, 1 or 2, with the proviso that if n is 2, all R substituents combined contain no more than 6 carbon atoms; A is tetrazol-5-yl or N-methyltetrazol-5-yl, B is a carbon-carbon bond, --CH 2 -- or ##STR39## or a derivative of a compound wherein A is tetrazol-5-yl, and derivative selected from a pharmaceutically acceptable alkali metal salt and an alkaline earth salt of the tetrazolyl moiety.
Claim 13
Independent Claim
125 words
A method of inhibiting bronchoconstriction due to an allergic response in a mammal wherein an antiallergic compound is administered in an amount sufficient to cause such inhibition, said antiallergic compound being of the formula ##STR38## wherein R is hydrogen, lower alkyl, lower alkoxy, lower alkylthio, halogen, amino, lower alkylamino, di(lower alkylamino), lower acylamido, or hydroxy, and n is 0, 1 or 2, with the proviso that if n is 2, all R substituents combined contain no more than 6 carbon atoms; A is tetrazol-5-yl or N-methyltetrazol-5-yl, B is a carbon-carbon bond, --CH 2 -- or ##STR39## or a derivative of a compound wherein A is tetrazol-5-yl, and derivative selected from a pharmaceutically acceptable alkali metal salt and an alkaline earth salt of the tetrazolyl moiety.
Claim 14
Dependent Claim
26 words
The compound 5-[3-(3,5-di-tert-butyl-4-hydroxyanilino)phenyl]-tetrazole or a derivative thereof selected from the group consisting of a pharmaceutically acceptable alkali metal salt and a pharmaceutically acceptable alkaline earth salt.
Claim 15
Dependent Claim
26 words
The compound 5-[3-(3,5-di-tert-butyl-4-hydroxyanilino)phenyl]-tetrazole or a derivative thereof selected from the group consisting of a pharmaceutically acceptable alkali metal salt and a pharmaceutically acceptable alkaline earth salt.
References Cited (Backward Citations)
CH7213A
Cited
US3313848A
Cited
GB1139332A
Cited
US4070484A
Cited
US4172151A
Cited
JPS54145648A
Cited
US4496590A
Cited
US4515980A
Cited
US4510139A
Cited
EP0181568A2
Cited
US4714776A
Cited
US4716178A
Cited
US4677113A
Cited
US4906662A
Cited
US4906662B1
Cited
US4710515A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-08-16 | 1997-02-15 | 1997-08-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-08-16 | 2001-02-15 | 2001-08-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-08-16 | 2005-02-15 | 2005-08-17 | $7700.00 | Window Closed / Lapsed |